MHRA grants conditional marketing authorization in UK for selinexor (Nexpovio) in combination with dexamethasone for treatment of adult patients with relapsed and or refractory multiple myeloma

Approval of this first-in-class, oral Selective Inhibitor of Nuclear Export is for use in patients who have received ≥ 4prior therapies and whose disease is refractory to ≥2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Source:

Biospace Inc.